The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as ...

The mNexspike vaccine is supplied as a single-dose prefilled syringe containing 1 dose of 0.2mL. The single 0.2mL dose should be administered at least 3 months after the last dose of COVID-19 vaccine.

Rep. Marjorie Taylor Greene, R-Ga., slammed the U.S. Food and Drug Administration's move to give the green light to Moderna's mNEXSPIKE COVID-19 vaccine. "Not MAHA at all!!!," the congresswoman ...

mNexspike becomes Moderna’s third FDA-approved product, joining Spikevax (original COVID-19 vaccine) and mResvia (RSV vaccine). Spikevax is approved/authorized for use by the FDA in individuals ...

FDA Approves Moderna’s mNEXSPIKE for High-Risk Populations: Moderna’s next-generation COVID-19 vaccine, mNEXSPIKE (mRNA-1283), has received FDA approval for adults aged 65 years and older and ...

US Food and Drug Administration (FDA) has approved mNEXSPIKE (mRNA-1283), a new vaccine against Covid-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one ...

The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...

Moderna’s mNEXSPIKE (mRNA-1283), a new COVID-19 vaccine, received FDA approval based on Phase III trial data showing higher relative vaccine efficacy than Spikevax. The vaccine will be available for ...

The FDA has approved a new COVID-19 vaccine developed by Moderna, offering a lower-dose option aimed at older adults and people with underlying health risks. The vaccine, named mNexspike, is part ...